glp-1 agonist examples Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 Receptor Agonists and Research

doi:10.1007/s00125-008-1195-5 35

[RxSS data

Wegovy injection showed weight loss of 15% in its key trial, versus 2% for placebo, while Zepbound showed 21% on its highest dose, compared with 3% for those on placebo

Regular follow-up appointments and adherence to monitoring protocols are essential to ensure the safe and effective use of these medications

Liraglutide attenuates diabetic cardiomyopathy via the ILK/PI3K/AKT/PTEN signaling pathway in rats with streptozotocin-induced type 2 diabetes mellitus

While randomized prevention trials are still needed, the consistency and biological coherence of current data support cautious optimism